Pharming announces positive data from paediatric clinical trial with RUCONEST®

RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema. “The results of this study provide important safety and efficacy data on the use of RUCONEST® in children and show good clinical concordance with results from adolescents and adults with HAE.” — Bruno Giannetti - COO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗